ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Clínica Universidad de Navarra at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Clínica Universidad de Navarra takes part in 11 sessions at ESMO 2026 in Madrid. Its work spans treatment research across ovarian, breast and other cancers, as well as clinical trial access and care decisions. It examines whether atropine can reduce treatment side effects in advanced breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Clínica Universidad de Navarra Pamplona, Spain | |
Private university hospital of the University of Navarra in Pamplona, Spain, with a cancer centre and a second site in Madrid. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Two-part, first-in-human trial evaluating a PVRIGxPD-L1 bispecific antibody in participants with selected advanced solid tumours Gastrointestinal cancersGynaecological cancersLung & thoracic cancers Poster Fri Oct 23 13:00–15:00 Unexpected burden of cholangiocarcinoma in a prospective population-based cohort in Gipuzkoa Province (Spain: 2010–2024) Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 09:10–09:30 Poster Sat Oct 24 12:00–12:45 Chair Sat Oct 24 14:45–16:15 Proffered paper: Gynaecological cancers Gynaecological cancers Chair Sun Oct 25 08:30–10:00 Rapid oral 1: Basic science and translational research Biomarkers & precision oncology Abstract Sun Oct 25 09:24–09:36 Invited Discussant 4247RO and 4514RO Biomarkers & precision oncology Satellite Sun Oct 25 13:20–13:40 Shared Decision-Making in Adjuvant Therapy: Balancing Recurrence Risk and Treatment Nursing & supportive care Satellite Sun Oct 25 14:00–14:20 What Matters Most to Patients? Bridging Communication Gaps to Improve Outcomes Nursing & supportive care Talk Mon Oct 26 08:45–09:00 Satellite Mon Oct 26 18:30–18:35 Introduction Lung & thoracic cancersGastrointestinal cancers Satellite Mon Oct 26 18:30–20:00 Revolution Medicines - Advances in RAS-targeted therapies: emerging clinical data and future directions in NSCLC and PDAC Lung & thoracic cancersGastrointestinal cancers Satellite Mon Oct 26 18:35–19:00 The role of RAS as an oncogenic driver in cancer pathogenesis and its therapeutic targeting Lung & thoracic cancersGastrointestinal cancers Satellite Mon Oct 26 19:45–20:00 Conclusions and Q&A Lung & thoracic cancersGastrointestinal cancers Talk Tue Oct 27 10:20–10:40 |
Find decision makers at Clínica Universidad de Navarra
Tell us what you sell and we’ll find the people at Clínica Universidad de Navarra most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction